Compare FIP & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIP | ETON |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 598.9M | 498.8M |
| IPO Year | N/A | 2018 |
| Metric | FIP | ETON |
|---|---|---|
| Price | $5.13 | $16.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $11.00 | ★ $29.67 |
| AVG Volume (30 Days) | ★ 1.7M | 270.8K |
| Earning Date | 10-30-2025 | 11-06-2025 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $439,767,000.00 | $70,316,000.00 |
| Revenue This Year | $60.92 | $113.27 |
| Revenue Next Year | $57.57 | $36.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 32.39 | ★ 102.77 |
| 52 Week Low | $3.10 | $11.09 |
| 52 Week High | $8.55 | $23.00 |
| Indicator | FIP | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 49.52 |
| Support Level | $4.63 | $16.13 |
| Resistance Level | $5.64 | $17.05 |
| Average True Range (ATR) | 0.33 | 0.76 |
| MACD | 0.13 | 0.16 |
| Stochastic Oscillator | 69.71 | 79.06 |
FTAI Infrastructure Inc is engaged in five segments; Railroad segment includes five freight railroads and one switching company that provide rail service to certain manufacturing and production facilities, the Jefferson Terminal segment consists of a multi-modal crude oil and refined products terminal and other related assets. Repauno segment consists of a 1,630-acre deep-water port located along the Delaware River with an underground storage cavern, a new multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities. Power and Gas segment is comprised of an equity method investment in Long Ridge, and Sustainability and Energy Transition segment is comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.